Tectonic Therapeutic (TECX) Projected to Post Earnings on Thursday

Tectonic Therapeutic (NASDAQ:TECX) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($1.11) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 3:00 PM ET.

Tectonic Therapeutic (NASDAQ:TECX) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.08. On average, analysts expect Tectonic Therapeutic to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Tectonic Therapeutic Stock Performance

Shares of TECX stock opened at $31.48 on Wednesday. The firm has a market cap of $591.19 million, a price-to-earnings ratio of -7.77 and a beta of 3.76. Tectonic Therapeutic has a 52 week low of $13.70 and a 52 week high of $36.03. The firm’s 50-day simple moving average is $23.55 and its two-hundred day simple moving average is $20.12.

Insider Transactions at Tectonic Therapeutic

In related news, CFO Daniel Lochner acquired 6,000 shares of the company’s stock in a transaction on Tuesday, February 10th. The stock was acquired at an average price of $21.61 per share, with a total value of $129,660.00. Following the acquisition, the chief financial officer directly owned 32,044 shares of the company’s stock, valued at approximately $692,470.84. This trade represents a 23.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, insider Marcella K. Ruddy sold 10,000 shares of the stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the transaction, the insider directly owned 69,747 shares of the company’s stock, valued at $2,092,410. This trade represents a 12.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 19,561 shares of company stock valued at $566,551. 9.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tectonic Therapeutic

A number of hedge funds have recently made changes to their positions in TECX. Orbimed Advisors LLC bought a new position in Tectonic Therapeutic during the fourth quarter valued at approximately $11,986,000. Vestal Point Capital LP purchased a new stake in shares of Tectonic Therapeutic during the 4th quarter worth approximately $6,842,000. Opaleye Management Inc. purchased a new stake in shares of Tectonic Therapeutic during the 4th quarter worth approximately $4,480,000. Millennium Management LLC boosted its position in shares of Tectonic Therapeutic by 726.4% during the 1st quarter. Millennium Management LLC now owns 237,938 shares of the company’s stock valued at $4,214,000 after acquiring an additional 209,145 shares during the last quarter. Finally, Kennedy Capital Management LLC bought a new position in shares of Tectonic Therapeutic during the 3rd quarter valued at approximately $3,276,000. 62.63% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TECX has been the subject of several research analyst reports. Lifesci Capital upgraded shares of Tectonic Therapeutic to a “strong-buy” rating in a research note on Thursday, February 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tectonic Therapeutic in a research note on Thursday, January 22nd. Finally, Truist Financial reduced their price objective on Tectonic Therapeutic from $64.00 to $60.00 and set a “buy” rating for the company in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.50.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.